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ABSTRACT 
CD96 has recently been shown to be a potent immune checkpoint molecule in mice, but a 
similar role in humans is not known. In this study, we provide a detailed map of CD96 
expression across human lymphocyte lineages, the kinetics of CD96 regulation on T‐cell 
activation and co‐expression with other conventional and emerging immune checkpoint 
molecules. We show that CD96 is predominantly expressed by T cells and has a unique 
lymphocyte expression profile. CD96high T cells exhibited distinct effector functions on 
activation. Of note, CD96 expression was highly correlated with T‐cell markers in primary 
and metastatic human tumors and was elevated on antigen‐experienced T cells and tumor‐
infiltrating lymphocytes. Collectively, these data demonstrate that CD96 may be a promising 
immune checkpoint to enhance T‐cell function against human cancer and infectious disease. 
INTRODUCTION 
Endogenous antitumor immunity is limited by the immunosuppressive tumor micro-
environment. However, reactivation of immune responses and overcoming immune 
tolerance have been achieved with antibody blockade of T‐cell co‐inhibitory receptors CTLA‐
4 and PD‐1 or the immunosuppressive ligand PD‐L1. While impressive overall response 
rates have been observed in cancer patients treated with these immune-therapies, 
combination treatment in patients with advanced malignant melanoma has produced even 
more significant anticancer effects.1, 2  Despite these impressive clinical responses, some 
patients do not respond to these therapies or do not demonstrate durable responses, 
suggesting that alternative immunosuppressive mechanisms must be targeted in 
combination to provide maximal therapeutic benefit across all individuals.  
Emerging data have demonstrated that members of the immunoglobulin (Ig)‐like receptor 
family, CD96, CD226 (DNAM‐1) and TIGIT, modulate NK and T‐cell activity in cancers and 
fine‐tune tumor immunosurveillance.3 These receptors interact with multiple cognate nectin 
and nectin‐like protein ligands, including CD155 and CD112, present in cancer cells, and 
reactive myeloid and antigen‐presenting cells (APC) within the tumor environment. The 
recognition of CD155 by CD226 is critical for antitumor immunity as demonstrated by the 
accelerated growth and metastasis of chemically or genetically induced tumors in CD226−/− 
mice.4, 5 
In mouse tumor models, anti‐TIGIT monoclonal antibodies (mAbs) have demonstrated 
profound antitumor efficacy when used in combination with anti‐PD‐L1 or anti‐PD1, and this 
mechanism is thought to involve the inhibitory function of TIGIT on regulatory T cells (Tregs)6 
and CD8+ T cells7; however, detailed pathway information is lacking. An additional role for 
TIGIT on NK‐cell‐mediated control of metastasis has also been defined8, 9; but again, 
detailed pathway information is lacking6.  In human melanoma tumor‐infiltrating lymphocytes 
(TILs), anti‐TIGIT mAbs augmented tumor antigen‐specific T‐cell degranulation, cytokine 
production and proliferation have been observed10.  An intrinsic inhibitory function of CD96 
was first shown using CD96‐deficient mice, where NK cells produced greater IFNȖ in 
response to lipopolysaccharide (LPS), IL12 or IL18 stimulation8.  A profound role for CD96 
in resistance to spontaneous or experimental lung metastases and MCA‐induced 
fibrosarcomas was demonstrated in CD96‐deficient mice or on blockade using CD96‐
specific mAbs in wild‐type mice8, 11.  Mechanistically, the function of CD96 was dependent 
on NK cells, IFNȖ and CDββ6, while an intrinsic function of CD96 on T cells was not 
addressed. It is therefore hypothesized that CD226 provides an activation signal to NK and 
T cells while TIGIT and CD96 may provide “inhibitory” signals thereby counterbalancing 
CD226 signaling. In the present study, we have expanded the existing experimental 
evidence suggesting an inhibitory function of mouse CD96 on immune‐mediated tumor 
control and provide a comprehensive expression analysis of CD96 in human immune cell 
subsets and in primary and metastatic tumors.  
RESULTS 
CD96 expression on lymphocytes is compartmentalized and unique 
It was recently shown that modulation of the CD96 pathway enhanced antitumor responses 
in mice11.  Whether these data can be translated to human cancer patients is unknown. 
Given the limited knowledge of CD96 expression profiles in humans, our first aim was to 
map CD96 expression across human lymphocyte subsets ex vivo and contrast expression 
with other immune checkpoints. Using five high‐dimensional flow cytometry panels, we 
performed a comprehensive dissection of CD96 expression using clone NK92.39 in the 
peripheral blood of healthy adults (Figure 1). Across the major lymphocyte lineages, T cells 
had the highest percentage of CD96+ cells (38 ± 9%) followed by NKCD56‐bright cells (21 ± 8%) 
(Figure 1a). Little or no CD96 was observed in B cells or monocytes. Interestingly, the overall 
CD96 expression hierarchy differed from the immune checkpoints TIGIT, CD226 and PD‐1 
(Figure 1a). Here, TIGIT expression was greatest in CD56+ T cells (48 ± 8%), followed by 
NKCD56‐dim (36 ± 15%). CD226 was highest in NKCD56‐bright cells (97.53 ± 1%) and PD‐1 
expression was highest in T cells (mean 7 ± 2%). We next determined CD96 expression on 
T cells by subtype and found CD96 was highest in mucosal‐associated invariant T (MAIT) 
cells (48 ± 18%) and CD8+ T cells (46 ± 12%) (Figure 1b). A notable deficiency of CD96 was 
observed in Ȗδ T cells and Tregs while TIGIT expression was enriched in these subsets. We 
next examined CD96 expression by T‐cell phenotype across CD4+ and CD8+ T‐cell lineages 
covering naïve, central memory, effector memory (EM) and effector memory RA (Figure 1c). 
In general, CD96 expression was higher in CD8+ T‐cell lineages, with EM (57 ± 16%) and 
central memory cells (42 ± 15%) showing the highest percentage of CD96+ cells.  
In CD4+ T cells, CD96 expression was also highest in the EM phenotype (52 ± 12%). Across 
T‐cell phenotypes, the hierarchical pattern of CD96 expression again differed from the Ig 
superfamily inhibitory receptor TIGIT but was similar to CD226 and PD‐1. Within CD4+ T‐
helper subtypes (Th1, Th2 and Th17) CD96 expression was highest on Th1 cells (15 ± 4%) 
with PD‐1 being the closest hierarchical match to CD96 (Figure 1d). Across all flow 
cytometric data, the relative differences in percent of CD96+ cells were matched by relative 
differences in mean fluorescence intensity (data not shown). This correlation between 
percentage expression and mean fluorescence intensity was also seen with PD‐1, TIGIT 
and CD226 (data not shown). Collectively, these data highlight selective CD96 distribution 
across human immune subsets and a generally distinct pattern compared with the related 
inhibitory receptor TIGIT, which correlated predominantly with regulatory cells (Treg and 
Th2).  
CD96 shows co‐expression bias with other checkpoint molecules 
The degree of co‐expression of other receptors with CD96 may provide insight into CD96 
functionality, especially given the potential to counterbalance CD226 action or to regulate 
other inhibitory receptor signaling. In resting CD8+ T cells, co‐expression of CD96 with 
CD226 was greater (29 ± 13%) than TIGIT (11% ± 5%) and PD‐1 (3 ± 2%) (data not shown). 
When gating on resting CD96highCD4+ T cells, the co‐expressing hierarchy was identical, 
comprising CD226 (35 ± 9%) followed by TIGIT (7 ± 3%) and PD‐1 (4 ± 1%) (data not 
shown). PD‐1 expression was generally low, which is consistent with a low level of antigen 
receptor stimulation in PBMC. Using resting or activated PBMC, we next concatenated the 
multiparametric flow data and performed viSNE analysis which allows visualization of high‐
dimensional single‐cell data. When examining resting CD8+ T‐cell subsets, we observed 
generally heterogeneous CD96 expression and the greatest overlap with CD226 expression 
and a relative enrichment of CD96 in the EM population (CD45RA− and CCR7−) (Figure 2a). 
CD96 was observed to be co‐expressed in resting PBMCs, with examples of CD96/TIGIT 
double‐positive cells observed in both PD‐1 positive and PD‐1 negative CD8+ T‐cell subsets. 
When examining resting CD4+ T‐cell subsets, we observed CD96 to cluster across the 
CD45RA− population, which again was similar to CD226 expression. In T‐cell helper 
subsets, both CD96 and CD226 expression were heterogeneous across Th1, Th2 and Th17 
cells (Figure 2b), although there was slightly lower expression of CD96 in Th2 cells. 
Conversely, PD‐1 and TIGIT expression clustered in a population of cells producing both 
IFNȖ and IL17 from phorbol myristate acetate/ionomycin‐activated T cells.  
CD96high T cells have a unique resting and activated transcription landscapes  
Given the enrichment of CD96 in certain T‐cell subsets, we next examined whether CD96 
expression correlated with unique cell phenotype and functional phenotype. To determine 
this, we sorted CD96high and CD96low cells across CD4+ and CD8+ memory T cells from 10 
healthy adults to high purity and quantified T‐cell transcriptional signatures. Through 
analysis of multidimensional immunological datasets12 , we found that CD96high and CD96low 
phenotypes exhibit unique transcriptional landscapes across both memory CD4+ and CD8+ 
lineages. From transcriptional signatures across cohorts, canonical correspondence 
analysis (CCA) showed CD8+ memory had higher variation (P = 0.007) compared with CD4+ 
memory (P = 0.04) (Figure 3a, b). Compared with paired CD96low sorts, CD96high CD8+ and 
CD4+ cells showed 53 and 46 differentially expressed genes, respectively. Of note, CD96 
RNA levels aligned with CD96high and CD96low cells which validated sort purity 
(Supplementary tables 3 and 4). Paired t‐test analysis of significantly expressed genes can 
be found in the supplementary material (Supplementary tables 3 and 4). Analysis using 
either CAA or support vector machine trained on the transcriptional profiles of either CD96high 
or CD96low T‐cells data suggests CD96‐associated phenotype is stronger in the CD8+ T‐cell 
compartment.  
For biological relevance, we next validated some of the top mRNA hits using multiparametric 
flow cytometry (Supplementary Figure 1a, b) on antigen‐specific CD8+ T cells using 
tetramers and relevant functional markers (Supplementary tables 1 and 3) across four 
donors. For GZMB and TBX21 (both within the top four most significant genes), we observed 
significant differences between CD96high and CD96low T‐cell populations that matched the 
direction seen in the NanoString profiling (Supplementary table 3).  
To identify possible differences in function between phenotypes, we sorted CD96high and 
CD96low memory CD8+ T cells from five donors and then activated each population with 
phorbol myristate acetate/ionomycin. Transcript analysis indicated differentially upregulated 
or downregulated signatures between CD96high and CD96low memory CD8+ T‐cells 
postactivation. Using CCA, we determined that activation significantly changed the CD96high 
(P = 0.01) and CD96low (P = 0.01) populations when comparing to a resting state. Using 
paired t‐tests on the fold change for each donor, we identified 14 genes that were 
differentially expressed between CD96high and CD96low T cells following activation 
(Supplementary table 4). CCA was not statistically significant between populations and, 
compared with ex vivo profiling, fewer genes were differentially expressed between CD96high 
and CD96low T‐cells postactivation, suggesting that the populations become more 
homogeneous after a strong activation signal. We have previously observed this “blending” 
phenotype when examining CD8+ and CD4+ human T‐cell lineages post‐T cell receptor 
(TCR) activation12.  Nonetheless, important functional genes were differentially expressed 
during activation including a strong downregulation of the protein tyrosine phosphatase 
CD45RA in CD96high cells (P = 0.0005) and upregulation of the pleotropic cytokine IL23A 
(P = 0.02) (Figure 3c). Likewise, activated CD96low T cells showed strong downregulation of 
the effector molecule granzyme M (GZMM) (P = 0.012) and immune checkpoint CTLA‐4 
(P = 0.037) postactivation (Figure 3c). Significant differences were also observed in effector 
molecules (GZMB) cytokines/chemokines (ILβ, IL17A, ILββ, IFNɣ and MIP‐1ȕ), integrins 
(ILTGA4), transcription factors (JUNB), cytolytic markers (CD160), the adenosine pathway 
(NT5E) and the JAK‐STAT pathway (JAK, STAT5B and STAT6) (Supplementary table 4). 
Overall, these data indicate that CD96high T cells have a distinctive ex vivo phenotype and 
exhibit a distinct functional phenotype when activated.  
CD96 is markedly upregulated on human T‐cells poststimulation 
We next examined CD96 expression kinetics and co‐expression with other immune 
checkpoint receptors in T cells after stimulation with CD3/CD28 microbeads. CD96 
expression (mean fluorescence intensity) on CD3+ T cells decreased at 4 h postactivation 
and remained low at D1 relative to ex vivo resting cells (Figure 4a). CD96 expression 
increased at D3 relative to the nadir between 4 h and D1, with almost all CD3+ T‐cells 
expressing CD96 at D5 (89 ± 9%) and persistently high expression to D7 (Figure 4a, b). The 
expression profile kinetics for CD226 was most closely matched to CD96, as CD226 
expression was reduced at D1 relative to ex vivo resting cells, followed by increased 
expression at D5 that persisted to D7 (Figure 4a, b). Upon activation, both TIGIT and PD‐1 
also demonstrated increased expression relative to ex vivo samples; however, overall the 
magnitude fold increase was substantially greater (~8‐fold) for CD96 compared with other 
markers. Analysis of mRNA for each of these immune receptors revealed TIGIT upregulation 
at 4 h postactivation, followed by PD‐1 and CD226 upregulation at D1, while any increase 
in CD96 was not observed until D3 (Figure 4c). A comparative analysis of CD96 protein 
expression kinetics (Figure 4a, b) with expression of CD96 mRNA (Figure 4c) suggested 
that protein expression was regulated as result of changes in the mRNA encoding CD96 
isoform 1, as CD96 isoform 2 mRNA remained low during the 7 days of T‐cell stimulation. 
Analysis of T cells at D7 poststimulation demonstrated an enhanced co‐expression of CD96 
with CD226 or TIGIT in both CD4+ and CD8+ T cells (Figure 5a and Supplementary Figure 
2a). An increased co‐expression of CD96 with PD‐1 was also observed in CD4+ T cells 
(Supplementary Figure 2a).  
Given this understanding of receptor expression dynamic upon broad TCR activation, we 
next investigated the co‐expression of CD96 with other immune receptors in two 
physiologically relevant systems. First, we determined CD96 expression was upregulated 
on CD4+ T cells in an allo‐mixed lymphocyte reaction after 5 days of culture (Supplementary 
Figure 2) while, reciprocally, the ligands CD112 and CD155 were upregulated on LPS‐
activated/matured dendritic cell (Supplementary Figure 2c). Second, we determined CD96 
expression was upregulated on peripheral blood‐derived CD4+ and CD8+ T cells from 
Epstein‐Barr virus‐positive donors stimulated in a memory recall assay with their autologous 
virus‐transformed LCL (Supplemental Figure 3a). Here, past experience showed that ~15% 
of T cells are antigen specific at day 7 of activation. Similar to the observations with 
CD3/CD28 stimulated T cells, we observed the greatest magnitude increases for CD96 and 
CD226 expression while marginal increases in TIGIT and PD‐1 were noted. Overall, there 
was an upregulation of CD96, TIGIT and CD226 expression within CD8+ and CD4+ and a 
significant increase in CD8+ T‐cells co‐expressing CD96 and PD‐1, CD96 and TIGIT or 
CD96 and CD226 (Figure 5b and Supplementary Figure 3a and b). In order to discriminate 
whether CD96 expression was associated with hyporesponsiveness as opposed to terminal 
differentiation, we analyzed co‐expression with TIGIT, CD226 or PD‐1 within proliferating 
(CellTrace Violet) (CTV−) versus nonproliferating (CTV+) populations after 7 days of 
stimulation with autologous LCL cells. Comparison of CTV+ with CTV− CD8+ T cells indicated 
a striking enrichment in CD96/TIGIT and CD96/CD226 double‐positive cells in the 
proliferative subset (Figure 5b). CD155 expression was observed on the LCL cell lines, 
although high variability (<0.5% to 47%) was observed between donors. CD155 was also 
variably expressed and upregulated on <10% of CD4+ and CD8+ T cells during the course 
of the assay (data not shown). 
CD96 is highly expressed in human tumors and correlates with antigen‐exposure and 
CD8+ T‐cell infiltration  
Given the observed focused expression and activation‐dependent upregulation of CD96 on 
human CD4+ and CD8+ T cells, we next analyzed the correlation between CD96 and T‐cell 
markers using mRNA expression data for primary and metastatic human melanoma 
(SKCM), breast invasive carcinoma (BRCA) and uterine corpus endometroid carcinoma 
from the Cancer Genome Atlas (TCGA). CD96 expression was highly correlated with CD3E, 
CD4 and CD8A in SKCM with similar CD96 levels observed in metastatic melanoma 
compared with primary tumors (Figure 6a). The correlation of CD96 mRNA with T‐cell 
markers was highly concordant across primary and metastatic melanoma [Spearman's 
correlation coefficient (ρ) = 0.88 and 0.89, 0.67 and 0.77, and 0.89 and 0.86, for CD3E, CD4 
and CD8A correlations between primary and metastatic melanoma, respectively] 
(Figure 6a). Notably, the correlation of CD96 and CD8A was higher than that observed for 
CD96 with CD4, although both associations were relatively high. Similarly, the correlation of 
CD96 and T‐cell markers was also high in BRCA and uterine corpus endometroid 
carcinoma, again with a relatively higher correlation with CD8A (P = 0.88 and 0.78) 
compared with CD4 (P = 0.74 and 0.68) for BRCA and uterine corpus endometroid 
carcinoma, respectively (Supplementary Figure 4). Analysis of each of the tumor types 
available from TCGA indicated that the correlation of CD96 with T‐cell markers was 
consistently observed, with the correlation with CD8A being particularly strong (24/31 tumor 
types demonstrating a Spearman's correlation coefficient >0.75) (Figure 6b). The high 
degree of correlation between CD96 and T‐cell markers was very similar to that observed 
with a prototypical Ig supefamily member, TIGIT, and T‐cell markers (Figure 6a, b and 
Figure 3). Collectively, the expression of CD96 and CD8A are higher when comparing 
metastatic tumor versus primary (Figure 6a) and between normal tissue and tumor 
(Supplementary Figure 4).  
CD96 expression and function has also been previously described on NK cells and a 
moderate correlation between CD96 and NCR1 was observed in SKCM, uterine corpus 
endometroid carcinoma and BRCA (P = 0.68, P = 0.52 and P = 0.69, respectively) 
(Figure 6a, b, Supplementary Figure 4). As with correlations between CD96 and T‐cell 
markers, the relative correlation of CD96 to a NK marker was similar to that observed for 
TIGIT and broadly observed across multiple tumor types (14/31 tumor types with 
Spearman's coefficient >0.5) (Figure 6b). In contrast to the concordant associations with T‐
cell markers between primary and metastatic melanoma, the ratio of either CD96 or TIGIT 
with NCR1 was significantly higher in metastatic versus primary lesions (P < 0.005 for both 
genes, Figure 6a).  
We next sought to determine whether CD96 was expressed on tetramer+ CD8+ T cells and 
CD8+ TILs. Using seven different herpesvirus‐specific tetramers on 12 samples, we found 
an average of 3.73% (±6%) of CD8+ T cells to be tetramer+ and 26.7% (±15.0%) of tetramer+ 
cells to be CD96+ (Supplementary table 1). Using CyTOF analysis and the CD96 mAb clone 
6F9 (instead of NK92.39), we next analyzed CD96 expression on CD3+ T cells in the PBMC 
and TILs of 13 colorectal cancer patients (Figure 6c). We found the frequency of CD96+ T 
cells was significant increased (57% ± 38%) (P = <0.0001) on TILs compared to those in 
peripheral blood. These CyTOF data and TCGA data suggest CD96 may be a druggable 
target for immune modulation in humans.  
DISCUSSION 
Immunotherapies that target the checkpoint inhibitory pathways PD‐1/PD‐L113 or CTLA‐414 
have demonstrated profound clinical benefit in cancer patients; however, there is only a 
subset of patients that experience durable responses upon monotherapy treatment. 
Combination immunotherapy targeting anti‐CTLA4 together with anti‐PD‐1 produced 
superior tumor responses and survival benefit in advanced melanoma, and demonstrates 
the importance of identifying and targeting nonredundant mechanisms of immune evasion 
by tumors15.  One feasible approach is to identify and block additional inhibitory receptors on 
hyporesponsive CD8+ T cells to augment antitumor function. Additional inhibitory receptors 
such as TIM‐3, LAG‐3, BTLA, Vista and B7‐H4 have been identified on chronically 
stimulated T cells and antibodies that block the respective ligands suggest these pathways 
contribute to CD8+ T‐cell dysfunction in functionally independent manners16-19.  Recent 
preclinical studies have identified CD96 and TIGIT as co‐inhibitory Ig superfamily receptors 
which function on lymphocytes to counterbalance the costimulatory CD226. CD226 plays a 
dominant and central role in NK and T‐cell‐mediated antitumor immunity3, 20 and recent 
murine work supports an inhibitory role for CD9621.   The functional interplay between the 
activating CD226 and the inhibitory CD96 and TIGIT receptors is reminiscent of the CTLA‐
4/CD28 counterbalance that is critical for the fine tuning of the immune response to cancer22.  
Demonstration of TIGIT expression and function in infiltrating T cells from human tumors10 
has provided evidence for the translational potential for this pathway in cancer treatment; 
however, similar expressional validation of CD96 in human immune cells has limited any 
translational progression of this target.  
In the present study, we provide a comprehensive expression analysis for CD96 across 
human immune mononuclear cell subsets and in the context of functional CD4+ and CD8+ 
T‐cell responses, including antitumor immunity. In PBMC from healthy donors, CD96 is 
predominantly expressed by CD8+ T cells and, across T‐cell subtypes, the pattern of 
expression is distinct from TIGIT and is generally most closely related to CD226 and PD‐1. 
Within CD4+ T cells, CD96 was more selectively expressed in Th1 cells compared with 
TIGIT, which was more highly expressed in Th2 and Treg cells. CD96 and CD226 were 
more highly expressed in CD8+ EM populations as compared with PD‐1 and TIGIT; however, 
PD‐1‐matched CD96 as the predominant marker for CD4+ and CD8+ EM populations. 
NanoString transcriptomic profiling across both CD4+ and CD8+ T cells determined that 
CD96 expression delineates a distinct T‐cell phenotype and distinct function, suggesting a 
relationship between the CD96 pathway and differentiation status and/or activation potential 
in vivo.  
The kinetics of CD96 expression in T cells upon TCR stimulation was distinct from the other 
inhibitory receptors TIGIT and PD‐1 and the “trough‐then‐peak” expression kinetics of CD96 
was similar to that observed for CD226. 
CD226 plays a central role in stimulating T‐cell and NK‐cell antitumor immunity and, at the 
same time, contributes to the limiting, immunomodulatory effects of TIGIT and CD967, 8.  
Each of these receptors binds to CD155, which is expressed by many solid and 
hematological malignancies; high CD155 expression has been reported to correlate with 
unfavorable outcomes in patients with melanoma23, lung adenocarcinoma24 or colorectal 
carcinoma25.  Significantly, while CD155 expression on tumors can be regulated through 
therapeutic intervention or by genotoxic or oxidative stress26, the additional expression of 
CD155 on reactive myeloid cells infiltrating human tumors is particularly prominent, 
exceeding levels observed for PD‐L110, 27. Competition of CD155 or CD112 ligand binding 
to inhibitory versus activating receptors can influence the net activation signal in 
lymphocytes23, although the potential for receptor/receptor homo‐ and heterodimerization 
between TIGIT, CD226 and CD96 may also contribute to the degree of activation. CD226 
expression is lower in chronically stimulated NK cells in a mouse multiple myeloma model28 
and CD8+ TILs from melanoma patients10, suggesting that a lower ratio of 
activating:inhibitory receptors will limit lymphocyte responses. In the present study, we 
observed that the kinetics and pattern of CD96 expression was similar to CD226 upon T‐
cell activation and, importantly, CD96 and CD226 were highly co‐expressed on T cells. The 
distinct kinetics and expression patterns of CD96 and TIGIT on T cells defined in the present 
study may proscribe a dominant inhibitory role for CD96 relatively later time‐points after 
antigen stimulation, while TIGIT may function earlier in T‐cell activation. Upon longer term 
antigen‐specific stimulation, we observed co‐expression of CD96 not only with the inhibitor 
receptor TIGIT but also with the stimulatory receptor CD226 on T cells, and these co‐
expressing populations were enriched in proliferating CD8+ T cells. Given these 
observations, it will be critical to elucidate the relative functional inhibition upon CD155 
ligation via TIGIT versus CD96 or any functional cross‐talk between receptors.  
Analysis of human tumors using gene expression analysis indicated that, similar to the 
inhibitory receptor TIGIT, elevated CD96 expression correlated with CD8 expression and 
infiltration of NK cells, although the association of T‐cell markers with CD96 was stronger. 
The identity and functional importance of CD96+ TILs, as well as any co‐expression of CD96 
with TIGIT in the tumor microenvironment, remain to be determined. Previous studies of 
CD96 biology suggested a role in mediating NK cell adhesion and activation, and we did 
note a moderate correlation of CD96 expression with NK markers; however, this was not as 
prominent as the T cell correlation observed here.  
Therapeutic targeting of the tumor immunosuppressive/co‐inhibitory pathways PD‐L1/PD‐1 
and CTLA‐4 with blocking antibodies have demonstrated durable responses and improved 
overall survival in cancer patients. Moreover, simultaneous targeting of multiple co‐inhibitory 
receptors (e.g. anti‐PD‐1 combined with anti‐CTLA‐4 mAbs) results in even greater 
antitumor immunity and anticancer effects1, 2.  Collectively, these data show that CD96 is 
predominantly expressed by human effector T cells, correlates with T‐cell markers in 
multiple human cancers and is enriched on antigen‐experienced T cells and TILs. These 
data support the idea that interference with CD96 signaling may be beneficial for 
immunotherapy against cancer and infectious disease.  
METHODS 
Flow cytometric profiling 
PBMCs were isolated by Ficoll–Hypaque centrifugation into RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS) (R10 medium). Blood donors were healthy, 
unrelated individuals who had given written informed consent. Approval was obtained from 
the QIMR Berghofer Medical Research Institute Human Ethics Committee (Brisbane, 
Australia). All cells were stained with LIVE/DEAD fixable aqua dead cell stain. Antibody 
details are listed in Supplementary table 2. The white blood cell flow panel comprised CD3‐
FITC, TCRαȕ‐BV786, CD56‐PE‐Cy7, CD16‐AF700, CD19‐BV421, CD14‐APC‐Cy7, 
CD155‐APC, CD96‐PE, TIGIT‐PerCP‐EF710, CD226‐BV711 and PD‐1‐BV604. The 
naïve/memory T‐cell flow panel comprised CD4‐FITC, CD8‐APC‐Cy7, TCRαȕ‐BV786, 
CD45RA‐PB, CCR7‐PE‐Cy7, CD96‐PE, TIGIT‐PerCP‐EF710, DNAM‐1‐BV711 and PD‐1‐
BV604. The T‐helper flow panel comprised CD4‐FITC, TCRαȕ‐BV786, IL17‐BV4β1, IFNȖ‐
AF700, IL4‐PE‐Cy7, CD96‐PE, TIGIT‐PerCP‐EF710, DNAM‐1‐BV711 (or‐PE) and PD‐1‐
BV6054. The Treg flow panel comprised CD3‐FITC, CD4‐PB, CD25‐PE‐Cy7, FoxP3‐APC, 
CD127‐BV786, CD96‐PE, TIGIT‐PerCP‐EF710, DNAM‐1‐BV711 and PD‐1‐BV604. The 
MAIT flow panel comprised CD3‐AF700, TCRȖδ‐BV421, TCRVα7.β‐FITC, CD161‐PerCP‐
Cy5.5, CD96‐PE, TIGIT‐APC, CD226‐BV711 and PD‐1‐BV605. All functional markers were 
gated relative to a fluorochrome‐matched isotype control. Human cells used for mixed 
lymphocyte reaction assays were stained with antibodies for CD3‐BV786, CD4‐FITC, CD8‐
AF700, CD14‐APC‐Cy7 CD96‐PE, TIGIT‐APC, PD‐1‐BV605, DNAM‐BV711, both on day 0 
and day 5 of the mixed lymphocyte reaction. Dendritic cells used for mixed lymphocyte 
reaction were stained for CD112‐APC and CD155‐Percp. For the tetramer experiments, 
1 μg of tetramer was added per test; tetramers included A1‐VTEHDTLLY (A1‐VTE), A2‐
NLVPMVATV (A2‐NLV), B7‐RPHERNGFTVL (B7‐RPH), B8‐ELKRKMIYM (B8‐ELK), B8‐
RAKFKQLL (B8‐RAK) and B35‐HPVGEADYFEY (B35‐HPV) labeled in PE or APC. Flow 
cytometric experiments were performed on a LSR Fortessa 5 (BD Biosciences, Franklin 
Lakes, NJ, USA) and analyzed using the FlowJo software (Tree Star Inc, Ashland, OR, 
USA).  
viSNE analysis 
FCS files of PBMC samples were concatenated and viSNE analysis was performed on the 
resulting file utilizing Cytobank (Cytobank Inc)29.  Analysis was performed on CD3+ cells and 
CD3+ CD4+ T cells for T‐effector subsets and T‐helper subsets, respectively. Analysis 
settings were iterations 1500–2000, theta 0.3 and perplexity 20–40. Generated consensus 
maps (viSNE maps of concatenated file) of T‐cell effector subsets and T‐cell helper subsets 
were then colored by all channels used for analysis to identify expression patterns of CD96, 
TIGIT, CD226 and PD‐1.  
CyTOF profiling 
Tissue samples were obtained from patients undergoing elective surgery for colorectal 
cancer at Dunedin Hospital, New Zealand. The study was approved by the Health and 
Disability Ethics Committee (#14/NTA/33) and all patients gave written informed consent 
prior to inclusion in the study in accordance with the Treaty of Helsinki. Specimens were 
dissected by a pathologist. 
Cryopreserved tumor dissociates (TD) and PBMCs from colorectal cancer patients were 
used for mass cytometric analyses. Samples were maintained in sterile phosphate‐buffered 
saline (PBS; Sigma‐Aldrich, St Louis, MO, USA) at 4°C for no longer than 3 hours until 
transportation on ice. Samples were washed in sterile PBS and suspended in RPMI 
(Invitrogen, Carlsbad, CA, USA) with 0.5 mg mL−1 collagenase (Invitrogen) and incubated 
at 37°C, 5% CO2, for 1 hour. The tissue was then mechanically dissociated with a sterile 
scalpel. The tissue suspension was removed from the well and filtered with a 70‐μm cell 
strainer (BD Falcon, Franklin Lakes, NJ) into a 50‐mL Falcon tube. Live immune cells were 
enriched using a three‐layer Ficoll‐Paque Plus (GE Healthcare, Chicago, IL, USA) gradient. 
Five milliliters of 75% Ficoll, 25% RPMI‐10 [RPMI supplemented with 100 μg mL−1 penicillin, 
100 μg mL−1 streptomycin and 55 μm 2‐mercaptoethanol (all from Invitrogen)] was layered 
on top of 5 mL 100% Ficoll. A quantity of 2.5 mL cell suspension in RPMI‐10 was layered 
above this. Ficoll gradients were then centrifuged at 800g for 20 min with no brake. PBMCs 
were also isolated using Ficoll separation. The buffy coat layer containing live immune cells 
was then carefully removed using a Pasteur pipette. Cells were frozen in freezing media 
(90% FCS (PAA Laboratories), 10% DMSO (Sigma‐Aldrich) in liquid nitrogen for storage. 
Samples were transported to Sydney on dry ice for a maximum of 12 h and stored at −80°C 
prior to staining.  
Samples were rapidly thawed, washed in FACS media (1× DPBS supplemented 1% FCS 
and 0.05% EDTA) and counted using Trypan Blue exclusion viability dye. Metal‐conjugated 
antibodies used in analysis are presented in the Key Resource Table. For some markers, 
fluorophore‐conjugated antibodies were used as primary antibodies, followed by secondary 
labeling with anti‐fluorophore metal‐conjugated antibodies. Antibodies were either 
purchased from Fluidigm or conjugated in‐house using MaxPar X8 reagent kits (Fluidigm), 
according to the manufacturer's protocol (Supplemental table 2). Conjugated antibodies 
were titrated for optimal concentration prior to use. Surface and intracellular antibody 
staining cocktail master mixes were prepared prior to each experiment. All antibody 
preparation and quality control were carried out by the Ramaciotti Facility for Human 
Systems Biology, Sydney. To most accurately compare protein expression levels between 
PBMC and TD we utilized a CD45‐based barcoding strategy30, whereby a given patient's TD 
and PBMCs were first stained separately with CD45‐Pd104 and CD45‐Pd110, separately 
then washed and combined for subsequent antibody staining steps. Cells were stained for 
mass cytometry analyses as described31.  Briefly, cells were stained with 1.25 μm Cell‐IDTM 
Cisplatin in PBS (Fluidigm) 3 min at room temperature and quenched by rapid addition of 
FCS. Cells were then washed twice in FACS buffer and then stained with a fluorophore‐
conjugated antibody cocktail for 20 min at 4°C. Following wash with FACS buffer, cells were 
stained with a metal‐conjugated surface stain antibody cocktail for 20 min at 4°C. Cells were 
then fixed and permeabilized using the FoxP3 Transcription Factor Staining Buffer Set, 
according to the manufacturer's protocol (eBiosciences, Santa Clara, CA, USA). Cells were 
subsequently stained with a metal‐conjugated intracellular antibody cocktail for 40 min at 
4°C. Cells were then washed twice, once in Perm/Wash buffer and once in FACS buffer. 
Cells were then fixed overnight in 4% paraformaldehyde solution containing DNA 
Intercalator (0.125 μM iridium‐191/193; Fluidigm). Prior to acquisition, cells were washed 
once in FACS and twice in dH2O. Cells were then diluted to 8 × 105 cells mL−1 in dH2O 
containing 10% EQ Four Element Calibration Beads (Fluidigm) and filtered. Cells were 
acquired at a rate of 200–400 cells s−1 using a CYTOF 2 Helios upgraded mass cytometer 
(Fluidigm). Flow Cytometry Standard (FCS) files were normalized to EQ bead signal and 
were then analyzed using FlowJo v10.2 (Tree Star Inc). TD and PBMC leukocytes were 
debarcoded manually in FlowJo.  
NanoString profiling 
CD96high and CD96low cells were sorted from memory CD4+ and CD8+ T cells using an Aria 
III (BD Biosciences) with FACSDiva (BD Biosciences). Total RNA from each T‐cell 
population was extracted using RNAzol RT (Astral Scientific), isopropanol (Sigma Aldrich) 
and ethanol (Sigma Aldrich). Briefly, cell lysate was mixed with UltraPure H2O (Sigma 
Aldrich) and centrifuged to separate RNA from other cell components. The clear liquid phase 
is then diluted with isopropanol and centrifuged to pellet RNA, washed with 75% ethanol, 
dried and resuspended in H2O for downstream use. Overnight nCounter codeset 
hybridization was performed as per the manufacturer's instruction using 100 ng of RNA, 
quantified by a Nanodrop 1000 (Thermo Scientific). The 135‐plex custom nCounter codeset 
covered key genes involved in human T‐cell recognition, survival, migration, adhesion, 
cytokine/chemokine secretion, differentiation and exhaustion. Following hybridization, 
samples were purified using an nCounter Prep Station before quantification with the 
nCounter Digital Analyzer. Multivariate analysis and network analysis were conducted using 
GraphPad PRISM (GraphPad software) and GMine software12. 
T‐cell kinetics profiling 
CD3+ T cells were purified from the PBMC of genetically unrelated donors using a negative 
selection Pan T cell Isolation Kit (Miltenyi Biotec). Isolated CD3+ T cells were activated using 
anti‐CD3/CD28 Dynabeads (ThermoFisher Scientific) at the final ratio of 1 bead: 5 cells in 
R10 medium. 200 000 activated T cells were plated in a V‐bottom 96‐well microtiter plate 
and harvested after 3 h, 6 h, day 1, day 3, day 5, day 7 and day 10 after stimulation. Media 
was replaced at day 5 and cells split into two wells. Nonstimulated T cells were used as 
controls. Prior to flow cytometric analysis and RNA extraction, Dynabeads beads were 
removed via magnetic separation. T cells were stained with anti‐CD3‐BV786, CD4‐PB, CD8‐
AF700, CD96‐PE, TIGIT‐APC, CD226‐BV711 and PD1 BV605. Relevant isotype controls 
were used in parallel. Dead cells were excluded by LIVE/DEAD fixable aqua dead cell stain. 
Flow cytometry was performed on a LSR Fortessa 4 (BD Biosciences).  
Real‐time PCR 
RNA was isolated from flow cytometry‐based sorted human T cells by an RNAeasy microkit 
(Qiagen) as per the manufacturer's instructions. One hundred nanograms of mRNA was 
used to synthesize cDNA using a sensiFAST cDNA synthesis Kit (Bioline). Predesigned 
Prime Time TaqMan qPCR assays were used to amplify mRNA and measure gene 
expression for CD96 (isoform 1 and 2), TIGIT, PD‐1 and CD226 (IDT Technologies) using 
6‐carboxyfluorescein as a reporter on the ABI ViiA 7 (Applied Biosystems) Real‐Time PCR 
system. cDNA was denatured and amplified at 95°C for 5 s and then 60°C for 30 s for 42 
cycles. Gene expression levels were normalized to the housekeeping gene ȕ‐2 
microglobulin (β(Ct value ȕβ m – Ct value gene of interest)).  
Mixed lymphocyte reaction 
CD14+ monocytes were isolated by positive selection using CD14 microbeads (Miltenyi 
Biotec) and cultured in vitro for 7 days with 300 IU mL−1 IL‐4 and 1000 IU mL−1 GM‐CSF 
(Preprotech Inc) to generate dendritic cells. Untouched T cells were isolated from PBMC 
with Rosette Sep (StemCell Technologies). Briefly, blood was collected and Rosette 
Sep™cocktail added and incubated for β0 min at room temperature. After dilution of the 
sample, a density gradient was performed and purified T cells collected from the enriched 
cell layer. CD3+ T cells (1 × 105) and allogeneic dendritic cell (1 × 104) were cocultured with 
in R10 medium. Flow cytomety was performed on a BD LSR Fortessa 4 (BD Biosciences) 
instrument and analyzed using the FlowJo software (Tree Star Inc).  
T‐cell priming using LCL feeders 
Short‐term Epstein‐Barr virus‐specific T‐cells cultures were established using LCL as 
stimulator cells. Donors were healthy adults and Epstein‐Barr virus seropositive. Briefly, 
2.5 × 105 purified (CD3+ or CD8+) T cells were seeded with irradiated autologous LCLs in a 
responder to stimulator ratio of 30:1 in a U‐bottom 96‐well microtiter plate in R10 medium 
supplemented with 45 IU mL−1 recombinant human IL‐2 (Proleukin; Chiron) at day 4. CD3+ 
T cells were purified by negative selection using RosetteSet T cell enrichment cocktail 
(STEMCELL Technologies). T cells were stained with CellTrace Violet (Thermo Fisher) in 
order to check proliferating (CTV−) versus nonproliferating (CTV+) populations after 7 days 
of stimulation with autologous LCL cells. Flow cytometric measures were performed on a 
BD LSR Fortessa 4 (BD Biosciences) instrument and analyzed using the FlowJo software 
(Tree Star Inc).  
Bioinformatics 
RNAseq data from the TCGA breast cancer and endometrial carcinoma project were 
obtained from the UCSC Cancer Genomics Hub. Raw RNA‐seq reads were trimmed for 
adapter sequences using Cutadapt and aligned to the GRCH37 assemble using STAR 
aligner. Quality control metrics were computed using RNA‐SeQC and expression was 
estimated using RSEM. The samples were normalized using library size estimation and 
corrected for differences in RNA composition using the method trimmed mean of M‐values 
implemented in the edgeR package32. To determine the correlation between expression of 
the CD96 and TIGIT genes with other genes of interest, we utilized RNA‐sequencing and 
data were normalized using the edgeR package. Spearman's rank correlation was estimated 
on the normalized counts. We considered ρ > 0.75 to be indicator of strong correlation, 
ρ < 0.75 but ρ > 0.5 for moderate correlation and ρ < 0.5 to be indicator of weak correlation. 
For calculation of CD96/CD3E ratios, we first transformed our data on to log2 scale and then 
estimated the log2 ratio of the normalized counts for CD96 and CD3E. A similar method was 
performed for other gene pairs. To calculate the differences in log ratios between the normal 
and tumor samples, we applied a linear regression model using standard R function. A P‐
value of <0.01 was considered as evidence of significance between normal and tumor 
samples.  
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Human CD96 expression is compartmentalized by lymphocyte lineage. PBMC from six 
healthy individuals were examined for CD96, TIGIT, CD226 and PD‐1 expression. (a) White 
blood cell panel gating B cells, NKbright cells, NKdim cells, CD56+ T cells, T cells and 
myeloid cells. (b) T‐cell subtype panels gated on CD4+ T cells, CD8+ T cells, Ȗδ T cells, 
Treg and MAIT cells. (c) T‐cell effector panel gated on naïve, central memory (CM), EM and 
TEMRA for CD4+ and CD8+ lineages. (d) Th subtype panel gated on Th1, Th2 and Th17 
cells post‐mitogen stimulation. Each immune checkpoint molecule was quantified relative to 
a fluorophore‐matched isotype control. Percentage positive values are shown. The 
experiment was conducted once. Data were acquired on a BD LSR Fortessa‐5 and analyzed 
using the FlowJo software. Each data point represents the percentage of cells positive from 





CD96 is co‐expressed with CD226. (a) viSNE plots showing CD4, CD8, CD45RA, CCR7, 
CD96, TIGIT, CD226 and PD‐1 co‐expression from six concatenated PBMC samples gated 
on CD3+ T cells. The experiment was conducted once. (b) viSNE plots showing IFNȖ, IL4, 
IL17, CD96, TIGIT, CD226 and PD‐1 co‐expression from six concatenated PBMC samples 
gated on CDγ+/CD4+ T cells that are cytokine positive. IFNȖ, IL4 and IL17 plots were gated 
on phorbol myristate acetate/ionomycin‐activated CD4+ T cells and cytokine‐negative cells 
have been removed from the analysis. Each phenotypic marker was quantified relative to a 
fluorophore‐matched isotype control. FCS files were analyzed using Cytobank. t‐distributed 
stochastic neighbor embedding (tSNE)‐1 and tSNE‐2 were used for embedding high‐
dimensional objects in two dimensions in such a way that similar objects are modeled by 




T‐cells expressing CD96 exhibit a distinct transcriptional landscape. CD96high and 
CD96low cells were sorted from effector memory (CD45RA−/CCR7−) CD4+ and CD8+ T 
cells to high purity from 10 individuals. RNA was extracted and run on a 135‐plex nCounter 
codeset. NanoString gene expression was normalized and genes filtered to exclude those 
with an average expression value <mean +2 SD of the negative controls. Significant, 
differentially expressed genes between populations are shown (Supplemental tables 2 & 3). 
CCA for CD8+ T cells (a) and CD4+ T cells (b) were determined using the Gmine 
software.12 (c) CD96high and CD96low cells were sorted from effector memory 
(CD45RA−/CCR7−) CD8+ T cells from five donors and stimulated with phorbol myristate 
acetate/ionomycin for 4 h. To determine differences in functional output, we used log2 of the 
fold change following activation between CD96high and CD96low CD8+ T cells. Four 
statistically significant examples are shown (*P < 0.05; **P < 0.01; ***P < 0.001). A support 
vector machine (SVM) trained on the transcriptional profiles of either CD96high or CD96low 
T cells and evaluated by leave‐one‐out cross‐validation achieved 95% and 80% accuracy in 





CD96 exhibits dynamic T‐cell activation kinetics. CD3+ T cells isolated from PBMC from 
three donors were stimulated with CD3/CD28 microbeads and CD96, TIGIT, CD226 and 
PD‐1 surface expression measured by flow cytometry at 4 h, day 1, 3, 5, 7 and 10 
postactivation. Receptor expression (plotted as percentage positive values) are shown (a) 
and representative histograms are shown in b. (c) The same in vitro cultures were also 
profiled for mRNA expression of CD96 (isoform 1 and 2), TIGIT, CD226 and PD‐1. Data are 








Co‐expression of CD96 and PD‐1, TIGIT and CD226/DNAM‐1 after T‐cell activation. The 
expression of CD96, CD226, TIGIT and PD‐1 was assessed on CD8+ T cells after activation 
using different stimuli. (a) Representative flow cytometry dot plots of CD8+ T cells measured 
ex vivo and after 7 days of activation with CD3/CD28 beads. (b) Representative flow 
cytometry dot plot of CTV+ and CTV− CD8+ T cells activated on coculture with autologous 
LCL cells for 7 days. Percentage positive values are shown. Data were acquired on a BD 










CD96 expression is strongly correlated with T‐cell markers in human cancer. (a) Correlation 
of CD96 or TIGIT with CDγΕ, CD4, CD8A or NCR1 in skin cutaneous melanoma (SKCM). 
Scatter plots show per‐gene count data normalized by library size. A ρ > 0.75 to be indicator 
of strong correlation and ρ < 0.75 but rho > 0.5 is an indicator of moderate correlation and 
ρ < 0.5 to be indicator of weak correlation. Analysis included primary tumors in black 
(n = 103) and metastatic tumors in red (n = 368). (b) CD96 and TIGIT gene expression is 
strongly correlated with T‐cell markers in TCGA datasets of human cancer. Gene expression 
analyses of human cancers were performed as described (in Methods) for all available and 
Spearman's correlations for CD96 or TIGIT with T cell (CDγΕ, CD4, CD8) and NK cell 
(NCR1) markers are shown. Analysis of each of the 31 tumor types available from TCGA 
indicate that the correlation of CD96 and TIGIT with T‐cell markers is consistently observed, 
with the correlation with CD8A being particularly strong (24/31 tumor types demonstrating a 
Spearman's correlation coefficient > 0.75 for CD96 and 20/31 tumor types demonstrating a 
Spearman's correlation coefficient > 0.75 for TIGIT). (c) CD96 expression on CD3+ T cells 
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